PICTET ASSET MANAGEMENT SA 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-03 11:56 am Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | PICTET ASSET MANAGEMENT SA | 0 0.000% | -128,714 (Position Closed) | Filing |
| 2022-02-10 11:10 am Purchase | 2022-02-10 | 13G | Neoleukin Therapeutics, Inc. NLTX | PICTET ASSET MANAGEMENT SA | 128,714 6.070% | 128,714 (New Position) | Filing |